Evidence map›Paper›PMID 33173583›Full record

ArticleClinical case reports2020

COVID-19 pneumonia and pulmonary microembolism in a patient with B-thalassemia major.

Marco Marziali, Michela Ribersani, Anna Annunziata Losardo, Fabrizio Taglietti, Pellegrina Pugliese, Alessandra Micozzi, Giuseppe Gentile, Antonio Angeloni

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Marco MarzialiHematology Policlinico Umberto 1 Sapienza Università di Roma Roma Italy.ORCID https://orcid.org/0000-0003-0565-7303
Michela RibersaniHematology Policlinico Umberto 1 Sapienza Università di Roma Roma Italy.
Anna Annunziata LosardoImmunohematology and Transfusion Medicine Unit Policlinico Umberto 1 Sapienza Università di Roma Roma Italy.
Fabrizio TagliettiSystemic and Immunocompromised Host Infection Unit National Institute for Infectious Diseases "L. Spallanzani" IRCCS Rome Italy.
Pellegrina PuglieseImmunohematology and Transfusion Medicine Unit Policlinico Umberto 1 Sapienza Università di Roma Roma Italy.
Alessandra MicozziDepartment of Translational and Precision Medicine Sapienza Università di Roma Roma Italy.
Giuseppe GentileDepartment of Translational and Precision Medicine Sapienza Università di Roma Roma Italy.
Antonio AngeloniDepartment of Experimental Medicine Sapienza Università di Roma Roma Italy.
Policlinico Umberto I · ITSapienza University of Rome · ITIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We think that thalassemia is not necessarily a cause of aggravation of the clinical course in COVID-19; however, certain key factors must be considered, such as the anemic condition, the likely pathogenic role of the virus on hemoglobin, and the hypercoagulable state to prevent any complications.

Indexed as

COVID‐19pneumoniathalassemia

Identifiers

PMID33173583
PMCPMC7646639
OpenAlexW3088683294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.